POINT Biopharma Provides Updated Efficacy and Safety Data

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A...

Related Keywords

Toronto ,Ontario ,Canada ,United Kingdom ,United States ,America ,Kim Chi ,Daniel Pearlstein ,Neil Fleshner ,Aaronr Hansen ,Scott Tagawa ,Oliver Sartor ,University Of Toronto ,Professor Of Medicine At Meyer Cancer Center ,University Of Queensland ,Nasdaq ,Biopharma Global Inc ,Chief Medical Officer ,Deputy Director ,Cancer Services ,Metro South Health ,Medical Oncologist ,Princess Alexandra Hospital ,Associate Professor ,North America ,Metastatic Castration Resistant Prostate Cancer ,Initial Results ,Weill Cornell Medicine ,Meyer Cancer Center ,Englj Med ,Private Securities Litigation Reform Act ,Relations Contact ,Nasdaq Pnt ,Point Biopharma ,Actinium 225 ,Clinical Trials ,Lutetium 177 ,Ncology ,Lutetium ,Oncology Clinical Trials ,Radiopharmaceutical ,Adioligand ,